Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
NCT ID: NCT06180096
Last Updated: 2023-12-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2023-03-07
2023-04-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Riociguat film coated tablets
Riociguat 2.5 mg film coated tablets
Riociguat film coated tablets
1 tablet of 2.5 mg Riociguat
Adempas Filmtabletten
1 tablet of 2.5 mg Riociguat
Adempas Filmtabletten
Adempas (Riociguat) 2.5 mg Filmtabletten
Riociguat film coated tablets
1 tablet of 2.5 mg Riociguat
Adempas Filmtabletten
1 tablet of 2.5 mg Riociguat
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Riociguat film coated tablets
1 tablet of 2.5 mg Riociguat
Adempas Filmtabletten
1 tablet of 2.5 mg Riociguat
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
3. BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one
4. significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while
5. 18.45 rounds up to 18.5).
6. Able to communicate effectively with study personnel.
7. Willing to provide written informed consent to participate in the study.
8. Non-smokers and non-tobacco users (i.e. having no past history of smoking and
9. tobacco consuming for at least one year prior to study).
10. Volunteer must have sitting systolic blood pressure at least 100 mmHg and sitting
11. diastolic blood pressure at least 60 mmHg during screening.
12. Volunteer must agree to either abstain from sexual intercourse or use an acceptable
13. method of birth control from screening until 4 weeks after the last study procedure.
14. All volunteers must be judged by the principal or sub-investigator or physician as
15. normal and healthy during a pre-study safety assessment performed within 28 days of
16. the first dose of study medication which will include:
1. A physical examination (clinical examination) with no clinically significant finding.
2. Results within normal limits or clinically non-significant for the following tests: Hematology, Biochemistry, Urinalysis, Immunological Tests Additional tests and/or examinations (apart from mentioned in protocol) may be performed, if necessary, based on principal investigator discretion. All results will be assessed against the current laboratory normal ranges at the time of testing and a copy of the normal ranges used will be included in the study documentation.
Exclusion Criteria
1. History of allergic responses to Riociguat or other related drugs, or any of its formulation ingredients.
2. Have significant diseases or clinically significant abnormal findings during screening \[medical history, physical examination (clinical examination), laboratory evaluations, ECG recording\].
3. Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
4. History or presence of bronchial asthma.
5. Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
6. A depot injection or implant of any drug within 3 months prior to the first dose of study medication.
7. Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see https://drug-interactions.medicine.iu.edu/MainTable.aspx).
8. History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
9. History of difficulty with donating blood or difficulty in accessibility of veins.
10. A positive hepatitis screen (includes subtypes B \& C).
11. A positive test result for HIV antibody.
12. Volunteers who have received a known investigational drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
13. Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or \>200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
14. History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
15. Intolerance to venipuncture
16. Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
17. Institutionalized volunteers.
18. Use of any prescribed medications \[including PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil, nitrates or nitric oxide donors (such as amyl nitrite), soluble guanylate cyclase stimulators\] within 14 days prior to the first dose of study medication.
19. Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
20. Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
21. Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeinecontaining sodas, colas, etc.), recreational drugs (including poppers), alcohol or other alcohol containing products within 120 hours prior to the first dose of study medication.
22. Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
23. Volunteer having serum creatinine higher than upper limit of normal range in screening.
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Humanis Saglık Anonim Sirketi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliantha Research Limited
Ahmedabad, Gujarat, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C1B02230
Identifier Type: -
Identifier Source: org_study_id